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Abstract
The Concise Guide to PHARMACOLOGY 2017/18 is the third in this series of biennial publications. This version provides concise overviews of the key properties of nearly 1800 human drug targets with an
emphasis on selective pharmacology (where available), plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of
target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website.
It provides a permanent, citable, point-in-time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.13882/full.
In addition to this overview, in which are identiﬁed ‘Other protein targets’ which fall outside of the subsequent categorisation, there are eight areas of focus: G protein-coupled receptors, ligand-gated
ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary
information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of
related targets from material contemporary to mid-2017, and supersedes data presented in the 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in
close conjunction with the Nomenclature Committee of the Union of Basic and Clinical Pharmacology (NC-IUPHAR), therefore, providing ofﬁcial IUPHAR classiﬁcation and nomenclature for human
drug targets, where appropriate.
Table of contents
S1 Overview
S6 Other Protein Targets
S6 Adiponectin receptors
S7 Blood coagulation components
S8 Non-enzymatic BRD containing proteins
S8 Carrier proteins
S9 CD molecules
S10 Methyllysine reader proteins
S11 Fatty acid-binding proteins
S13 Notch receptors
S13 Regulators of G protein Signaling (RGS) proteins
S14 Sigma receptors
S15 Tubulins
S17 G protein-coupled receptors
S19 Orphan and other 7TM receptors
S19 Class A Orphans
S28 Class C Orphans
S28 Taste 1 receptors
S29 Taste 2 receptors
S30 Other 7TM proteins
S31 5-Hydroxytryptamine receptors
S34 Acetylcholine receptors (muscarinic)
S36 Adenosine receptors
S37 Adhesion Class GPCRs
S39 Adrenoceptors
S43 Angiotensin receptors
S44 Apelin receptor
S45 Bile acid receptor
S46 Bombesin receptors
S47 Bradykinin receptors
S48 Calcitonin receptors
S50 Calcium-sensing receptor
Searchable database: http://www.guidetopharmacology.org/index.jsp Overview S1
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13882/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2017/18: Overview. British Journal of Pharmacology (2017) 174, S1–S16
S51 Cannabinoid receptors
S52 Chemerin receptor
S53 Chemokine receptors
S57 Cholecystokinin receptors
S58 Class Frizzled GPCRs
S59 Complement peptide receptors
S60 Corticotropin-releasing factor receptors
S61 Dopamine receptors
S63 Endothelin receptors
S64 G protein-coupled estrogen receptor
S65 Formylpeptide receptors
S66 Free fatty acid receptors
S67 GABAB receptors
S69 Galanin receptors
S70 Ghrelin receptor
S71 Glucagon receptor family
S72 Glycoprotein hormone receptors
S73 Gonadotrophin-releasing hormone receptors
S75 GPR18, GPR55 and GPR119
S76 Histamine receptors
S77 Hydroxycarboxylic acid receptors
S78 Kisspeptin receptor
S79 Leukotriene receptors
S81 Lysophospholipid (LPA) receptors
S82 Lysophospholipid (S1P) receptors
S83 Melanin-concentrating hormone receptors
S84 Melanocortin receptors
S85 Melatonin receptors
S86 Metabotropic glutamate receptors
S88 Motilin receptor
S89 Neuromedin U receptors
S90 Neuropeptide FF/neuropeptide AF receptors
S91 Neuropeptide S receptor
S92 Neuropeptide W/neuropeptide B receptors
S93 Neuropeptide Y receptors
S94 Neurotensin receptors
S95 Opioid receptors
S97 Orexin receptors
S98 Oxoglutarate receptor
S98 P2Y receptors
S101 Parathyroid hormone receptors
S101 Platelet-activating factor receptor
S102 Prokineticin receptors
S103 Prolactin-releasing peptide receptor
S104 Prostanoid receptors
S106 Proteinase-activated receptors
S107 QRFP receptor
S108 Relaxin family peptide receptors
S110 Somatostatin receptors
S111 Succinate receptor
S111 Tachykinin receptors
S113 Thyrotropin-releasing hormone receptors
S113 Trace amine receptor
S114 Urotensin receptor
S115 Vasopressin and oxytocin receptors
S117 VIP and PACAP receptors
S130 Ligand-gated ion channels
S131 5-HT3 receptors
S133 Acid-sensing (proton-gated) ion channels (ASICs)
S135 Epithelial sodium channels (ENaC)
S137 GABAA receptors
S142 Glycine receptors
S145 Ionotropic glutamate receptors
S150 IP3 receptor
S151 Nicotinic acetylcholine receptors
S154 P2X receptors
S156 ZAC
S160 Voltage-gated ion channels
S161 CatSper and Two-Pore channels
S163 Cyclic nucleotide-regulated channels
S164 Potassium channels
S165 Calcium- and sodium-activated potassium channels
S166 Inwardly rectifying potassium channels
S169 Two P domain potassium channels
S171 Voltage-gated potassium channels
S175 Ryanodine receptor
S176 Transient Receptor Potential channels
S186 Voltage-gated calcium channels
S189 Voltage-gated proton channel
S190 Voltage-gated sodium channels
S195 Other ion channels
S196 Aquaporins
S197 Chloride channels
S197 ClC family
S199 CFTR
S200 Calcium activated chloride channel
S201 Maxi chloride channel
S202 Volume regulated chloride channels
S204 Connexins and Pannexins
S206 Sodium leak channel, non-selective
S208 Nuclear hormone receptors
S209 1A. Thyroid hormone receptors
S210 1B. Retinoic acid receptors
S210 1C. Peroxisome proliferator-activated receptors
S211 1D. Rev-Erb receptors
S212 1F. Retinoic acid-related orphans
S213 1H. Liver X receptor-like receptors
S214 1I. Vitamin D receptor-like receptors
S214 2A. Hepatocyte nuclear factor-4 receptors
S215 2B. Retinoid X receptors
S216 2C. Testicular receptors
S216 2E. Tailless-like receptors
S217 2F. COUP-TF-like receptors
S218 3B. Estrogen-related receptors
S218 4A. Nerve growth factor IB-like receptors
S219 5A. Fushi tarazu F1-like receptors
S220 6A. Germ cell nuclear factor receptors
S220 0B. DAX-like receptors
S221 Steroid hormone receptors
S221 3A. Estrogen receptors
S222 3C. 3-Ketosteroid receptors
S225 Catalytic receptors
S226 Cytokine receptor family
S227 IL-2 receptor family
S229 IL-3 receptor family
S230 IL-6 receptor family
S231 IL-12 receptor family
S232 Prolactin receptor family
S233 Interferon receptor family
S234 IL-10 receptor family
S235 Immunoglobulin-like family of IL-1 receptors
S236 IL-17 receptor family
S237 GDNF receptor family
S237 Integrins
S241 Natriuretic peptide receptor family
S242 Pattern recognition receptors
S243 Toll-like receptor family
S244 NOD-like receptor family
S246 Receptor tyrosine kinases (RTKs)
S247 Type I RTKs: ErbB (epidermal growth factor) receptor
family
S248 Type II RTKs: Insulin receptor family
S249 Type III RTKs: PDGFR, CSFR, Kit, FLT3 receptor family
S250 Type IV RTKs: VEGF (vascular endothelial growth factor)
receptor family
S251 Type V RTKs: FGF (ﬁbroblast growth factor) receptor family
S252 Type VI RTKs: PTK7/CCK4
S252 Type VII RTKs: Neurotrophin receptor/Trk family
S253 Type VIII RTKs: ROR family
Searchable database: http://www.guidetopharmacology.org/index.jsp Overview S2
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13882/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2017/18: Overview. British Journal of Pharmacology (2017) 174, S1–S16
S254 Type IX RTKs: MuSK
S254 Type X RTKs: HGF (hepatocyte growth factor)
receptor family
S255 Type XI RTKs: TAM (TYRO3-, AXL- and MER-TK) receptor
family
S255 Type XII RTKs: TIE family of angiopoietin receptors
S256 Type XIII RTKs: Ephrin receptor family
S257 Type XIV RTKs: RET
S257 Type XV RTKs: RYK
S258 Type XVI RTKs: DDR (collagen receptor) family
S258 Type XVII RTKs: ROS receptors
S259 Type XVIII RTKs: LMR family
S259 Type XIX RTKs: Leukocyte tyrosine kinase (LTK) receptor
family
S260 Type XX RTKs: STYK1
S260 Receptor serine/threonine kinase (RSTK) family
S261 Type I receptor serine/threonine kinases
S262 Type II receptor serine/threonine kinases
S262 Type III receptor serine/threonine kinases
S262 RSTK functional heteromers
S264 Receptor tyrosine phosphatase (RTP) family
S266 Tumour necrosis factor (TNF) receptor family
S272 Enzymes
S275 Kinases (EC 2.7.x.x)
S276 Rho kinase
S276 Protein kinase C (PKC)
S277 Alpha subfamily
S277 Delta subfamily
S278 Eta subfamily
S278 FRAP subfamily
S279 Cyclin-dependent kinase (CDK) family
S279 CDK4 subfamily
S279 GSK subfamily
S280 Polo-like kinase (PLK) family
S280 STE7 family
S281 Abl family
S281 Ack family
S281 Janus kinase (JakA) family
S282 Src family
S283 Tec family
S283 RAF family
S284 Peptidases and proteinases
S284 A1: Pepsin
S284 A22: Presenilin
S285 C14: Caspase
S285 M1: Aminopeptidase N
S285 M2: Angiotensin-converting (ACE and ACE2)
S286 M10: Matrix metallopeptidase
S286 M12: Astacin/Adamalysin
S287 M28: Aminopeptidase Y
S287 M19: Membrane dipeptidase
S288 S1: Chymotrypsin
S288 T1: Proteasome
S289 S8: Subtilisin
S289 S9: Prolyl oligopeptidase
S290 Acetylcholine turnover
S291 Adenosine turnover
S292 Amino acid hydroxylases
S293 L-Arginine turnover
S294 2.1.1.- Protein arginine N-methyltransferases
S294 Arginase
S294 Arginine:glycine amidinotransferase
S295 Dimethylarginine dimethylaminohydrolases
S295 Nitric oxide synthases
S296 Carboxylases and decarboxylases
S297 Carboxylases
S298 Decarboxylases
S300 Catecholamine turnover
S302 Ceramide turnover
S303 Serine palmitoyltransferase
S303 Ceramide synthase
S304 Sphingolipid 4-desaturase
S304 Sphingomyelin synthase
S305 Sphingomyelin phosphodiesterase
S305 Neutral sphingomyelinase coupling factors
S306 Ceramide glucosyltransferase
S306 Acid ceramidase
S307 Neutral ceramidases
S307 Alkaline ceramidases
S308 Ceramide kinase
S309 Chromatin modifying enzymes
S309 2.1.1.- Protein arginine N-methyltransferases
S310 3.5.1.- Histone deacetylases (HDACs)
S310 Cyclic nucleotide turnover/signalling
S310 Adenylyl cyclases (ACs)
S312 Exchange protein activated by cyclic AMP (EPACs)
S312 Nitric oxide (NO)-sensitive (soluble) guanylyl cyclase
S313 Phosphodiesterases, 3’,5’-cyclic nucleotide (PDEs)
S317 Cytochrome P450
S317 CYP1 family
S318 CYP2 family
S318 CYP3 family
S319 CYP4 family
S320 CYP5, CYP7 and CYP8 families
S320 CYP11, CYP17, CYP19, CYP20 and CYP21 families
S321 CYP24, CYP26 and CYP27 families
S322 CYP39, CYP46 and CYP51 families
S323 Endocannabinoid turnover
S323 N-Acylethanolamine turnover
S324 2-Acylglycerol ester turnover
S325 Eicosanoid turnover
S325 Cyclooxygenase
S326 Prostaglandin synthases
S327 Lipoxygenases
S328 Leukotriene and lipoxin metabolism
S329 GABA turnover
S331 Glycerophospholipid turnover
S331 Phosphoinositide-speciﬁc phospholipase C
S332 Phospholipase A2
S334 Phosphatidylcholine-speciﬁc phospholipase D
S335 Lipid phosphate phosphatases
S335 Phosphatidylinositol kinases
S336 1-phosphatidylinositol 4-kinase family
S336 Phosphatidylinositol-4-phosphate 3-kinase family
S337 Phosphatidylinositol 3-kinase family
S337 Phosphatidylinositol-4,5-bisphosphate 3-kinase family
S338 1-phosphatidylinositol-3-phosphate 5-kinase family
S338 Type I PIP kinases (1-phosphatidylinositol-4-phosphate
5-kinase family)
S339 Type II PIP kinases (1-phosphatidylinositol-5-phosphate
4-kinase family)
S339 Haem oxygenase
S340 Hydrogen sulphide synthesis
S341 Hydrolases
S342 Inositol phosphate turnover
S342 Inositol 1,4,5-trisphosphate 3-kinases
S343 Inositol polyphosphate phosphatases
S343 Inositol monophosphatase
S344 Lanosterol biosynthesis pathway
S346 Nucleoside synthesis and metabolism
S347 Sphingosine 1-phosphate turnover
S348 Sphingosine kinase
S348 Sphingosine 1-phosphate phosphatase
S349 Sphingosine 1-phosphate lyase
S349 Thyroid hormone turnover
S350 1.14.11.29 2-oxoglutarate oxygenases
S351 1.14.13.9 kynurenine 3-monooxygenase
S352 2.4.2.30 poly(ADP-ribose)polymerases
S352 2.5.1.58 Protein farnesyltransferase
S353 3.5.1.- Histone deacetylases (HDACs)
S354 3.5.3.15 Peptidyl arginine deiminases (PADI)
S354 RAS subfamily
S355 4.2.1.1 Carbonate dehydratases
S355 5.99.1.2 DNA Topoisomerases
S360 Transporters
S362 ATP-binding cassette transporter family
S362 ABCA subfamily
S363 ABCB subfamily
Searchable database: http://www.guidetopharmacology.org/index.jsp Overview S3
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13882/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2017/18: Overview. British Journal of Pharmacology (2017) 174, S1–S16
S365 ABCC subfamily
S366 ABCD subfamily of peroxisomal ABC transporters
S367 ABCG subfamily
S368 F-type and V-type ATPases
S368 F-type ATPase
S368 V-type ATPase
S369 P-type ATPases
S369 Na+/K+-ATPases
S369 Ca2+-ATPases
S370 H+/K+-ATPases
S370 Cu+-ATPases
S370 Phospholipid-transporting ATPases
S371 Major facilitator superfamily (MFS) of transporters
S371 SLC superfamily of solute carriers
S372 SLC1 family of amino acid transporters
S372 Glutamate transporter subfamily
S374 Alanine/serine/cysteine transporter subfamily
S375 SLC2 family of hexose and sugar alcohol
S375 Class I transporters
S376 Class II transporters
S377 Proton-coupled inositol transporter
S377 SLC3 and SLC7 families of heteromeric amino acid
transporters (HATs)
S377 SLC3 family
S378 SLC7 family
S379 SLC4 family of bicarbonate transporters
S380 Anion exchangers
S380 Sodium-dependent HCO−3 transporters
S381 SLC5 family of sodium-dependent glucose transporters
S381 Hexose transporter family
S382 Choline transporter
S383 Sodium iodide symporter, sodium-dependentmultivitamin
transporter and sodium-coupled monocarboxylate
transporters
S384 Sodium myo-inositol cotransporter transporters
S385 SLC6 neurotransmitter transporter family
S385 Monoamine transporter subfamily
S386 GABA transporter subfamily
S387 Glycine transporter subfamily
S389 Neutral amino acid transporter subfamily
S390 SLC8 family of sodium/calcium exchangers
S390 SLC9 family of sodium/hydrogen exchangers
S391 SLC10 family of sodium-bile acid co-transporters
S392 SLC11 family of proton-coupled metal ion transporters
S393 SLC12 family of cation-coupled chloride transporters
S395 SLC13 family of sodium-dependent sulphate/carboxylate
transporters
S395 SLC14 family of facilitative urea transporters
S396 SLC15 family of peptide transporters
S398 SLC16 family of monocarboxylate transporters
S399 SLC17 phosphate and organic anion transporter family
S399 Type I sodium-phosphate co-transporters
S400 Sialic acid transporter
S400 Vesicular glutamate transporters (VGLUTs)
S401 Vesicular nucleotide transporter
S401 SLC18 family of vesicular amine transporters
S403 SLC19 family of vitamin transporters
S403 SLC20 family of sodium-dependent phosphate transporters
S404 SLC22 family of organic cation and anion transporters
S404 Organic cation transporters (OCT)
S405 Organic zwitterions/cation transporters (OCTN)
S406 Organic anion transporters (OATs)
S407 Urate transporter
S407 SLC23 family of ascorbic acid transporters
S409 SLC24 family of sodium/potassium/calcium exchangers
S409 SLC25 family of mitochondrial transporters
S410 Mitochondrial di- and tri-carboxylic acid transporter
subfamily
S411 Mitochondrial amino acid transporter subfamily
S412 Mitochondrial phosphate transporters
S412 Mitochondrial nucleotide transporter subfamily
S413 Mitochondrial uncoupling proteins
S414 Miscellaneous SLC25 mitochondrial transporters
S414 SLC26 family of anion exchangers
S415 Selective sulphate transporters
S415 Chloride/bicarbonate exchangers
S416 Anion channels
S416 Other SLC26 anion exchangers
S417 SLC27 family of fatty acid transporters
S418 SLC28 and SLC29 families of nucleoside transporters
S418 SLC28 family
S419 SLC29 family
S420 SLC30 zinc transporter family
S421 SLC31 family of copper transporters
S422 SLC32 vesicular inhibitory amino acid transporter
S422 SLC33 acetylCoA transporter
S423 SLC34 family of sodium phosphate co-transporters
S424 SLC35 family of nucleotide sugar transporters
S425 SLC36 family of proton-coupled amino acid transporters
S426 SLC37 family of phosphosugar/phosphate exchangers
S427 SLC38 family of sodium-dependent neutral amino acid
transporters
S427 System A-like transporters
S428 System N-like transporters
S428 Orphan SLC38 transporters
S429 SLC39 family of metal ion transporters
S430 SLC40 iron transporter
S430 SLC41 family of divalent cation transporters
S431 SLC42 family of Rhesus glycoprotein ammonium
transporters
S432 SLC43 family of large neutral amino acid transporters
S433 SLC44 choline transporter-like family
S433 SLC45 family of putative sugar transporters
S434 SLC46 family of folate transporters
S435 SLC47 family ofmultidrug and toxin extrusion transporters
S436 SLC48 heme transporter
S436 SLC49 family of FLVCR-related heme transporters
S437 SLC50 sugar transporter
S438 SLC51 family of steroid-derived molecule transporters
S438 SLC52 family of riboﬂavin transporters
S439 SLCO family of organic anion transporting polypeptides
S442 Patched family
Searchable database: http://www.guidetopharmacology.org/index.jsp Overview S4
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13882/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2017/18: Overview. British Journal of Pharmacology (2017) 174, S1–S16
Introduction
In order to allow clarity and consistency in pharmacology, there is
a need for a comprehensive organisation and presentation of the
targets of drugs. This is the philosophy of the IUPHAR/BPS Guide
to PHARMACOLOGY presented on the online free access database
(http://www.guidetopharmacology.org/). This database is sup-
ported by the British Pharmacological Society (BPS), the Interna-
tional Union of Basic and Clinical Pharmacology (IUPHAR), the
University of Edinburgh and previously the Wellcome Trust. Data
included in the Guide to PHARMACOLOGY are derived in large
part from interactions with the subcommittees of the Nomencla-
ture Committee of the International Union of Basic and Clinical
Pharmacology (NC-IUPHAR). A major inﬂuence on the develop-
ment of the database was Tony Harmar (1951-2014), who worked
with a passion to establish the curators as a team of highly in-
formed and informative individuals, with a focus on high-quality
data input, ensuring a suitably validated dataset. The Editors of
the Concise Guide have compiled the individual records, in con-
cert with the team of Curators, drawing on the expert knowl-
edge of these latter subcommittees. The tables allow an indication
of the status of the nomenclature for the group of targets listed,
usually previously published in Pharmacological Reviews. In the
absence of an established subcommittee, advice from several
prominent, independent experts has generally been obtained to
produce an authoritative consensus on nomenclature, which at-
tempts to ﬁt in within the general guidelines from NC-IUPHAR.
This current edition, the Concise Guide to PHARMACOLOGY
2017/18, is the latest snapshot of the database in print form, fol-
lowing on from the Concise Guide to PHARMACOLOGY 2015/16.
It contains data drawn from the online database as a rapid
overview of the major pharmacological targets. Thus, there are
many fewer targets presented in the Concise Guide compared to
the online database. The priority for inclusion in the Concise
Guide is the presence of quantitative pharmacological data. This
means that often orphan family members are not presented in the
Concise Guide, although structural information is available on the
online database. The organisation of the data is tabular (where ap-
propriate) with a standardised format, where possible on a single
page, intended to aid understanding of, and comparison within, a
particular target group. The Concise Guide is intended as an initial
resource, with links to additional reviews and resources for greater
depth and information. Pharmacological and structural data focus
primarily on human gene products, wherever possible, with links
to HGNC gene nomenclature and UniProt IDs. In a few cases,
where data from human proteins are limited, data from other
species are indicated. Pharmacological tools listed are prioritised
on the basis of selectivity and availability. That is, agents (agonists,
antagonists, inhibitors, activators, etc.) are included where they
are both available (by donation or from commercial sources, now
or in the near future) AND the most selective. The Concise Guide
is divided into nine sections, which comprise pharmacological tar-
gets of similar structure/function. These are G protein-coupled
receptors, ligand-gated ion channels, voltage-gated ion channels,
other ion channels, catalytic receptors, nuclear hormone recep-
tors, enzymes, transporters and other protein targets. We hope
that the Concise Guide will provide for researchers, teachers and
students a state-of-the art source of accurate, curated information
on the background to their work that they will use in the Introduc-
tions to their Research Papers or Reviews, or in supporting their
teaching and studies. We recommend that any citations to in-
formation in the Concise Guide are presented in the following
format:
Alexander SPH et al. (2017). The Concise Guide to PHARMACOL-
OGY 2017/18: Overview. Br J Pharmacol 174: S1–S16.
In this overview are listed protein targets of pharmacological inter-
est, which are not G protein-coupled receptors, ligand-gated ion
channels, voltage-gated ion channels, ion channels, nuclear hor-
mone receptors, catalytic receptors, transporters or enzymes.
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Other Protein Targets
Family structure
S6 Adiponectin receptors
– B-cell lymphoma 2 (Bcl-2) protein family
S7 Blood coagulation components
– Bromodomain-containing proteins
S7 Non-enzymatic BRD containing proteins
S8 Carrier proteins
S9 CD molecules
– Chromatin-interacting transcriptional repressors
S10 Methyllysine reader proteins
– Circadian clock proteins
– Claudins
– EF-hand domain containing
S11 Fatty acid-binding proteins
– G-alpha family G(q) subfamily
– Heat shock proteins
– Immunoglobulins
– Inhibitors of apoptosis (IAP) protein family
– Kelch-like proteins
– Kinesins
– Leucine-rich repeat proteins
– Lymphocyte antigens
– Mitochondrial-associated proteins
– Myosin binding proteins
– Non-catalytic pattern recognition receptors
– Absent in melanoma (AIM)-like receptors (ALRs)
– C-type lectin-like receptors (CLRs)
– Other pattern recognition receptors
S12 Notch receptors
– Pentaxins
– Serum pentaxins
S13 Regulators of G protein Signaling (RGS) proteins
S14 R4 family
– Repulsive guidance molecules
– Reticulons and associated proteins
– Ribosomal factors
S14 Sigma receptors
S15 Tubulins
– Tumour-associated proteins
– WD repeat-containing proteins
Adiponectin receptors
Other protein targets → Adiponectin receptors
Overview: Adiponectin receptors (provisional nomen-
clature, ENSFM00500000270960) respond to the 30 kDa
complement-related protein hormone adiponectin (also known
as ADIPOQ: adipocyte, C1q and collagen domain-containing
protein; ACRP30, adipose most abundant gene transcript 1;
apM-1; gelatin-binding protein: Q15848) originally cloned from
adipocytes [49]. Although sequence data suggest 7TM domains,
immunological evidence indicates that, contrary to typical 7TM
topology, the carboxyl terminus is extracellular, while the amino
terminus is intracellular [90]. Signalling through these receptors
appears to avoid G proteins; modelling based on the crystal struc-
tures of the adiponectin receptors suggested ceramidase acivity,
which would make these the ﬁrst in a new family of catalytic re-
ceptors [93].
Nomenclature Adipo1 receptor Adipo2 receptor
HGNC, UniProt ADIPOR1, Q96A54 ADIPOR2, Q86V24
Rank order of potency globular adiponectin (ADIPOQ, Q15848) > adiponectin (ADIPOQ, Q15848) globular adiponectin (ADIPOQ, Q15848) = adiponectin (ADIPOQ, Q15848)
Comments: T-Cadherin (CDH13, P55290) has also been suggested to be a receptor for (hexameric) adiponectin [33].
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Further reading on Adiponectin receptors
Fisman EZ et al. (2014) Adiponectin: a manifold therapeutic target for metabolic syndrome, dia-
betes, and coronary disease? Cardiovasc Diabetol 13: 103 [PMID:24957699]
Matsuda M et al. (2014) Roles of adiponectin and oxidative stress in obesity-associated metabolic
and cardiovascular diseases. Rev Endocr Metab Disord 15: 1-10 [PMID:24026768]
Ruan H et al. (2016) Adiponectin signaling and function in insulin target tissues. J Mol Cell Biol 8:
101-9 [PMID:26993044]
Wang Y et al. (2017) Cardiovascular Adiponectin Resistance: The Critical Role of Adiponectin Re-
ceptor Modiﬁcation. Trends Endocrinol Metab 28: 519-530 [PMID:28473178]
Zhao L et al. (2014) Adiponectin and insulin cross talk: the microvascular connection. Trends
Cardiovasc Med 24: 319-24 [PMID:25220977]
Blood coagulation components
Other protein targets → Blood coagulation components
Overview: Coagulation as a process is interpreted as a mechanism for reducing excessive blood loss through the generation of a gel-like clot local to the site of injury. The process involves the activation,
adhesion (see Integrins), degranulation and aggregation of platelets, as well as proteins circulating in the plasma. The coagulation cascade involves multiple proteins being converted to more active forms
from less active precursors, typically through proteolysis (see Proteases). Listed here are the components of the coagulation cascade targetted by agents in current clinical usage.
Nomenclature coagulation factor V coagulation factor VIII serpin family C member 1
HGNC, UniProt F5, P12259 F8, P00451 SERPINC1, P01008
Selective activators – – heparin (pKd 7.8) [26], fondaparinux (pKd 7.5) [62], dalteparin [32], danaparoid
[16, 56], enoxaparin [19], tinzaparin [20]
Selective inhibitors drotrecogin alfa [36, 37] drotrecogin alfa [36, 37] –
Further reading on Blood coagulation components
Astermark J. (2015) FVIII inhibitors: pathogenesis and avoidance. Blood 125: 2045-51
[PMID:25712994]
Girolami A et al. (2017) New clotting disorders that cast new light on blood coagulation and may
play a role in clinical practice. J Thromb Thrombolysis 44: 71-75 [PMID:28251495]
Rana K et al. (2016) Blood ﬂow and mass transfer regulation of coagulation. Blood Rev 30: 357-68
[PMID:27133256]
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Non-enzymatic BRD containing proteins
Other protein targets → Bromodomain-containing proteins → Non-enzymatic BRD containing proteins
Overview: Bromodomains bind proteins with acetylated lysine residues, such as histones, to regulate gene transcription. Listed herein are examples of bromodomain-containing proteins for which
sufﬁcient pharmacology exists.
Nomenclature bromodomain adjacent
to zinc ﬁnger domain 2A
bromodomain adjacent
to zinc ﬁnger domain 2B
CREB binding protein polybromo 1 SWI/SNF related, matrix associated,
actin dependent regulator of
chromatin, subfamily a, member 4
HGNC, UniProt BAZ2A, Q9UIF9 BAZ2B, Q9UIF8 CREBBP, Q92793 PBRM1, Q86U86 SMARCA4, P51532
Selective inhibitors GSK2801 (pKd 6.6) [73] GSK2801 (pKd 6.9) [73] I-CBP112 (pKd 6.8) [72] PFI-3 (pKd 7.3) [79] PFI-3 (pKd 7.1) [79]
Further reading on Non-enzymatic BRD containing proteins
Brand M et al. (2015) Small molecule inhibitors of bromodomain-acetyl-lysine interactions. ACS
Chem. Biol. 10: 22-39 [PMID:25549280]
Fujisawa T et al. (2017) Functions of bromodomain-containing proteins and their roles in home-
ostasis and cancer Nat Rev Mol Cell Biol 18: 246-262 [PMID:28053347]
Nicholas DA et al. (2017) BET bromodomain proteins and epigenetic regulation of inﬂamma-
tion: implications for type 2 diabetes and breast cancer. Cell Mol Life Sci 74: 231-243
[PMID:27491296]
Theodoulou NH et al. (2016) Clinical progress and pharmacology of small molecule bromodomain
inhibitors. Curr Opin Chem Biol 33: 58-66 [PMID:27295577]
Theodoulou NH et al. (2016) Progress in the Development of non-BET Bromodomain Chemical
Probes. ChemMedChem 11: 477-87 [PMID:26749027]
Carrier proteins
Other protein targets → Carrier proteins
Overview: Transthyretin (TTR) is a homo-tetrameric protein
which transports thyroxine in the plasma and cerebrospinal ﬂuid
and retinol (vitamin A) in the plasma. Many disease causing
mutations in the protein have been reported, many of which
cause complex dissociation and protein mis-assembly and depo-
sition of toxic aggregates amyloid ﬁbril formation [63]. These
amyloidogenic mutants are linked to the development of patho-
logical amyloidoses, including familial amyloid polyneuropathy
(FAP) [4, 14], familial amyloid cardiomyopathy (FAC) [34], amy-
loidotic vitreous opacities, carpal tunnel syndrome [54] and oth-
ers. In old age, non-mutated TTR can also form pathological
amyloid ﬁbrils [88]. Pharmacological intervention to reduce or
prevent TTR dissociation is being pursued as a theapeutic strat-
egy. To date one small molecule kinetic stabilising molecule
(tafamidis) has been approved for FAP, and is being evaluated in
clinical trials for other TTR amyloidoses.
Nomenclature transthyretin
HGNC, UniProt TTR, P02766
Common abreviation TTR
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Further reading on Carrier proteins
Alshehri B et al. (2015) The diversity of mechanisms inﬂuenced by transthyretin in neuro-
biology: development, disease and endocrine disruption. J Neuroendocrinol 27: 303-23
[PMID:25737004]
Delliere S et al. (2017) Is transthyretin a good marker of nutritional status? Clin Nutr 36: 364-370
[PMID:27381508]
Galant NJ et al. (2017) Transthyretin amyloidosis: an under-recognized neuropathy and cardiomy-
opathy. Clin Sci (Lond) 131: 395-409 [PMID:28213611]
CD molecules
Other protein targets → CD molecules
Overview: Cluster of differentiation refers to an attempt to catalogue systematically a series of over 300 cell-surface proteins associated with immunotyping. Many members of the group have identiﬁed
functions as enzymes (for example, see CD73 ecto-5’-nucleotidase) or receptors (for example, see CD41 integrin, alpha 2b subunit). Many CDs are targetted for therapeutic gain using antibodies for the
treatment of proliferative disorders. A full listing of all the Clusters of Differentiation is not possible in the Guide to PHARMACOLOGY; listed herein are selected members of the family targetted for
therapeutic gain.
Nomenclature CD2 CD3e CD20 (membrane-spanning
4-domains, subfamily A,
member 1)
CD33 CD52
HGNC, UniProt CD2, P06729 CD3E, P07766 MS4A1, P11836 CD33, P20138 CD52, P31358
Common
abreviation
– – – SIGLEC-3 –
Selective inhibitors alefacept (Inhibition)
[17, 53]
– – – –
Antibodies – catumaxomab (Binding)
[43], muromonab-CD3
(Binding) [25],
otelixizumab (Binding) [9]
ofatumumab (Binding) (pKd
9.9) [47], rituximab (Binding)
(pKd 8.5) [75],
ibritumomab tiuxetan (Binding),
obinutuzumab (Binding) [3, 66],
tositumomab (Binding)
lintuzumab (Binding)
(pKd ∼10) [10],
gemtuzumab ozogamicin
(Binding) [7]
alemtuzumab
(Binding) [24, 79]
Searchable database: http://www.guidetopharmacology.org/index.jsp CD molecules S9
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Nomenclature CD80 CD86 cytotoxic T-lymphocyte-associated
protein 4 (CD152)
programmed cell death 1 (CD279) CD300a
HGNC, UniProt CD80, P33681 CD86, P42081 CTLA4, P16410 PDCD1, Q15116 CD300A, Q9UGN4
Common
abreviation
– – CTLA-4 PD-1 –
Antibodies – – ipilimumab (pKd >9) [28],
tremelimumab (pKd 8.9) [30]
pembrolizumab (pKd ∼10) [11], nivolumab
(pKd 9.1) [28, 38, 40]
–
Comment: The endogenous ligands for human PD-1 are programmed cell death 1 ligand 1 (PD-L1 akaCD274 (CD274, Q9NZQ7)) and programmed cell death 1 ligand 2 (PD-L2; PDCD1LG2). These ligands
are cell surface peptides, normally involved in immune system regulation. Expression of PD-1 by cancer cells induces immune tolerance and evasion of immune system attack. Anti-PD-1 monoclonal
antibodies are used to induce immune checkpoint blockade as a therapeutic intervention in cancer, effectively re-establishing immune vigilance. pembrolizumab was the ﬁrst anti-PD-1 antibody to be
approved by the US FDA.
Further reading on CD molecules
Gabius HJ et al. (2015) The glycobiology of the CD system: a dictionary for translatingmarker desig-
nations into glycan/lectin structure and function. Trends Biochem Sci 40: 360-76 [PMID:25981696]
Methyllysine reader proteins
Other protein targets → Chromatin-interacting transcriptional repressors → Methyllysine reader proteins
Overview: Methyllysine reader proteins bind to methylated proteins, such as histones, allowing regulation of gene expression.
Nomenclature l(3)mbt-like 3 (Drosophila)
HGNC, UniProt L3MBTL3, Q96JM7
Selective agonists UNC1215 [35]
Further reading on Methyllysine reader proteins
Liu K et al. (2015) Epigenetic targets and drug discovery Part 2: Histone demethylation and DNA
methylation. Pharmacol. Ther. 151: 121-40 [PMID:25857453]
Milosevich N et al. (2016) Chemical Inhibitors of Epigenetic Methyllysine Reader Proteins. Bio-
chemistry 55: 1570-83 [PMID:26650180]
Sadakierska-Chudy A et al. (2015) A comprehensive view of the epigenetic landscape part I: DNA
methylation, passive and active DNA demethylation pathways and histone variants. Neurotox
Res 27: 84-97 [PMID:25362550]
Teske KA et al. (2017) Methyllysine binding domains: Structural insight and small molecule probe
development. Eur J Med Chem 136: 14-35 [PMID:28478342]
Zahnow CA et al. (2016) Inhibitors of DNA Methylation, Histone Deacetylation, and Histone
Demethylation: A Perfect Combination for Cancer Therapy. Adv Cancer Res 130: 55-111
[PMID:27037751]
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Fatty acid-binding proteins
Other protein targets → Fatty acid-binding proteins
Overview: Fatty acid-binding proteins are lowmolecular weight
(100-130 aa) chaperones for long chain fatty acids, fatty acyl CoA
esters, eicosanoids, retinols, retinoic acids and related metabo-
lites and are usually regarded as being responsible for allowing
the otherwise hydrophobic ligands to be mobile in aqueous me-
dia. These binding proteins may perform functions extracellu-
larly (e.g. in plasma) or transport these agents; to the nucleus
to interact with nuclear receptors (principally PPARs and retinoic
acid receptors [70]) or for interaction with metabolic enzymes.
Although sequence homology is limited, crystallographic stud-
ies suggest conserved 3D structures across the group of binding
proteins.
Nomenclature fatty acid binding protein 1 fatty acid binding protein 2 fatty acid binding protein 3 fatty acid binding protein 4
HGNC, UniProt FABP1, P07148 FABP2, P12104 FABP3, P05413 FABP4, P15090
Rank order of
potency
stearic acid, oleic acid >
palmitic acid, linoleic acid >
arachidonic acid, α-linolenic acid [67]
stearic acid >
palmitic acid,oleic acid >
linoleic acid > arachidonic acid,
α-linolenic acid [67]
stearic acid, oleic acid, palmitic acid
> linoleic acid, α-linolenic acid,
arachidonic acid [67]
oleic acid, palmitic acid,
stearic acid, linoleic acid >
α-linolenic acid, arachidonic acid
[67]
Inhibitors fenoﬁbrate (pKi 7.6) [12] – Rat,
fenoﬁbric acid (pKi 6.5) [12] – Rat,
HTS01037 (pKi 5.1) [30] – Mouse
– – –
Selective inhibitors – – – HM50316 (pKi >9) [46]
Comments A broader substrate speciﬁcity than
other FABPs, binding two fatty acids
per protein [82].
Crystal structure of the rat FABP2
[69].
Crystal structure of the human
FABP3 [91].
–
Nomenclature fatty acid binding
protein 5
fatty acid binding
protein 6
fatty acid binding
protein 7
peripheral myelin
protein 2
fatty acid binding
protein 9
fatty acid binding
protein 12
HGNC, UniProt FABP5, Q01469 FABP6, P51161 FABP7, O15540 PMP2, P02689 FABP9, Q0Z7S8 FABP12, A6NFH5
Comments Crystal structure of the
human FABP5 [31].
Able to transport
bile acids [95].
Crystal structure of the
human FABP7 [5].
In silico modelling
suggests that
PMP2/FABP8 can bind
both fatty acids and
cholesterol [50].
– –
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Nomenclature retinol binding
protein 1
retinol binding protein 2 retinol binding
protein 3
retinol binding protein 4 retinol binding
protein 5
retinol binding
protein 7
HGNC, UniProt RBP1, P09455 RBP2, P50120 RBP3, P10745 RBP4, P02753 RBP5, P82980 RBP7, Q96R05
Rank order of
potency
– stearic acid >
palmitic acid, oleic acid,
linoleic acid,
α-linolenic acid,
arachidonic acid [68]
– – – –
Inhibitors – – – A1120 (pIC50 7.8) [86] – –
Nomenclature retinaldehyde binding protein 1 cellular retinoic acid binding protein 1 cellular retinoic acid binding protein 2
HGNC, UniProt RLBP1, P12271 CRABP1, P29762 CRABP2, P29373
Rank order of potency 11-cis-retinal, 11-cis-retinol > 9-cis-retinal,
13-cis-retinal, 13-cis-retinol, all-trans-retinal,
retinol [15]
tretinoin > alitretinoin stearic acid >
palmitic acid, oleic acid, linoleic acid,
α-linolenic acid, arachidonic acid [68]
–
Comments: Although not tested at all FABPs, BMS309403 exhibits high afﬁnity for FABP4 (pIC50 8.8) compared to FABP3 or FABP5 (pIC50 <6.6) [21, 81]. HTS01037 is reported to interfere with FABP4
action [30]. Ibuprofen displays some selectivity for FABP4 (pIC50 5.5) relative to FABP3 (pIC50 3.5) and FABP5 (pIC50 3.8) [48]. Fenoﬁbric acid displays some selectivity for FABP5 (pIC50 5.5) relative to
FABP3 (pIC50 4.5) and FABP4 (pIC50 4.6) [48]. Multiple pseudogenes for the FABPs have been identiﬁed in the human genome.
Further reading on Fatty acid-binding proteins
Gajda AM et al. (2015) Enterocyte fatty acid-binding proteins (FABPs): different functions of
liver and intestinal FABPs in the intestine. Prostaglandins Leukot. Essent. Fatty Acids 93: 9-16
[PMID:25458898]
Glatz JF. (2015) Lipids and lipid binding proteins: a perfect match. Prostaglandins Leukot. Essent.
Fatty Acids 93: 45-9 [PMID:25154384]
Hotamisligil GS et al. (2015) Metabolic functions of FABPs-mechanisms and therapeutic implica-
tions. Nat Rev Endocrinol 11: 592-605 [PMID:26260145]
Matsumata M et al. (2016) Fatty acid binding proteins and the nervous system: Their impact on
mental conditions. Neurosci. Res. 102: 47-55 [PMID:25205626]
Osumi T et al. (2016) Heart lipid droplets and lipid droplet-binding proteins: Biochemistry, physi-
ology, and pathology. Exp Cell Res 340: 198-204 [PMID:26524506]
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Notch receptors
Other protein targets → Notch receptors
Overview: The canonocal Notch signalling pathway has four
type I transmembrane Notch receptors (Notch1-4) and ﬁve lig-
ands (DLL1, 2 and 3, and Jagged 1-2). Eachmember of this highly
conserved receptor family plays a unique role in cell-fate deter-
mination during embryogenesis, differentiation, tissue pattern-
ing, proliferation and cell death [2]. As the Notch ligands are
also membrane bound, cells have to be in close proximity for
receptor-ligand interactions to occur. Cleavage of the intracel-
lular domain (ICD) of activated Notch receptors by γ-secretase
is required for downstream signalling and Notch-induced tran-
scriptional modulation [18, 57, 71, 89]. This is why γ-secretase
inhibitors can be used to downregulate Notch signalling and
explains their anti-cancer action. One such small molecule is
RO4929097 [47], although development of this compound has
been terminated following an unsuccessful Phase II single agent
clinical trial in metastatic colorectal cancer [78].
Aberrant Notch signalling is implicated in a number of human
cancers [41, 59, 74, 85]. Pharmaceutical inhibitors of Notch sig-
nalling such as demcizumab and tarextumab are being actively
investigated as novel anti-cancer agents [64].
Nomenclature notch 1 notch 2 notch 3 notch 4
HGNC, UniProt NOTCH1, P46531 NOTCH2, Q04721 NOTCH3, Q9UM47 NOTCH4, Q99466
Comments Various types of activating and inactivating NOTCH1 mutations have been
reported to be associated with human diseases, for example: aortic valve
disease [23, 52], Adams-Oliver syndrome 5 [76], T-cell acute lymphoblastic
leukemia (T-ALL) [87], chronic lymphocytic leukemia (CLL) [65] and head and
neck squamous cell carcinoma [1, 77].
– – Notch 4 is a potential
therapeutic molecular
target for triple-negative
breast cancer [42, 55].
Further reading on Notch receptors
Borggrefe T et al. (2016) The Notch intracellular domain integrates signals from Wnt, Hedgehog,
TGFbeta/BMP and hypoxia pathways. Biochim Biophys Acta 1863: 303-313 [PMID:26592459]
Cheng YL et al. (2015) Emerging roles of the gamma-secretase-notch axis in inﬂammation. Phar-
macol Ther 147: 80-90 [PMID:25448038]
Palmer WH et al. (2015) Ligand-Independent Mechanisms of Notch Activity. Trends Cell Biol 25:
697-707 [PMID:26437585]
Previs RA et al. (2015) Molecular pathways: translational and therapeutic implications of the Notch
signaling pathway in cancer. Clin Cancer Res 21: 955-61 [PMID:25388163]
Takebe N et al. (2015) Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical
update. Nat Rev Clin Oncol 12: 445-464 [PMID:25850553]
Regulators of G protein Signaling (RGS) proteins
Other protein targets → Regulators of G protein Signaling (RGS) proteins
Overview: Regulators of G protein signalling (RGS) proteins increase the deactivation rates of G protein signalling pathways through enhancing the GTPase activity of the G protein alpha subunit.
Interactions through protein:protein interactions of many RGS proteins have been identiﬁed for targets other than heteromeric G proteins. The 20 RGS proteins are commonly divided into four families
(R4, R7, R12 and RZ) based on sequence and domain homology. Described here is RGS4 for which a number of pharmacological inhibitors have been described.
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Nomenclature regulator of G-protein signaling 4
HGNC, UniProt RGS4, P49798
Common abreviation RGS4
Selective inhibitors RGS4 inhibitor 11b (pIC50 7.8) [83], CCG-50014 (pIC50 7.5) [8, 83], RGS4 inhibitor 13 (pIC50 7.3) [83]
Further reading on RGS proteins
Sethakorn N et al. (2010) Non-canonical functions of RGS proteins. Cell Signal 22: 1274-81
[PMID:20363320]
Sjogren B (2017) The evolution of regulators of G protein signalling proteins as drug targets - 20
years in the making: IUPHAR Review 21. Br J Pharmacol 174: 427-437 [PMID:28098342]
Sjogren B et al. (2010) Thinking outside of the "RGS box": new approaches to therapeutic targeting
of regulators of G protein signaling. Mol Pharmacol 78: 550-7 [PMID:20664002]
Turner EM et al. (2012) Small Molecule Inhibitors of Regulator of G Protein Signalling (RGS) Pro-
teins. ACS Med Chem Lett 3: 146-150 [PMID:22368763]
Sigma receptors
Other protein targets → Sigma receptors
Overview: Although termed ‘receptors’, the evidence for coupling through conventional signalling pathways is lacking. Initially described as a subtype of opioid receptors, there is only a modest
pharmacological overlap and no structural convergence with the G protein-coupled receptors; the crystal structure of the sigma1 receptor [94] suggests a trimeric structure of a single short transmembrane
domain traversing the endoplasmic reticulum membrane, with the bulk of the protein facing the cytosol. A wide range of compounds, ranging from psychoactive agents to antihistamines, have been
observed to bind to these sites.
Nomenclature sigma non-opioid intracellular receptor 1 σ2
HGNC, UniProt SIGMAR1, Q99720 –
Selective agonists PRE-084 [80], (+)-SKF 10.047 –
Selective antagonists NE-100 (pIC50 8.4) [60], BD-1047 (pIC50 7.4) [51] –
Labelled ligands [3H]pentazocine (Agonist) [3H]-di-o-tolylguanidine (Agonist)
Comments: (-)-pentazocine also shows activity at opioid receptors. The sigma2 receptor has recently been reported to be TMEM97 Q5BJF2 [92] , a 4TM protein partner of NPC1, the Niemann-Pick C1
protein, a 13TM cholesterol-binding protein.
Further reading on Sigma receptors
ChuUB et al. (2016) Biochemical Pharmacology of the Sigma-1 Receptor. Mol Pharmacol 89: 142-53
[PMID:26560551]
Gris G et al. (2015) Sigma-1 receptor and inﬂammatory pain. Inﬂamm Res 64: 377-81
[PMID:25902777]
Rousseaux CG et al. (2015) Sigma receptors [sigmaRs]: biology in normal and diseased states. J
Recept Signal Transduct Res 1-62 [PMID:26056947]
Su TP et al. (2016) The Sigma-1 Receptor as a Pluripotent Modulator in Living Systems. Trends
Pharmacol Sci 37: 262-78 [PMID:26869505]
van Waarde A et al. (2015) Potential applications for sigma receptor ligands in cancer diagnosis
and therapy. Biochim Biophys Acta 1848: 2703-14 [PMID:25173780]
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Tubulins
Other protein targets → Tubulins
Overview: Tubulins are a family of intracellular proteins most commonly associated with microtubules, part of the cytoskeleton. They are exploited for therapeutic gain in cancer chemotherapy as
targets for agents derived from a variety of natural products: taxanes, colchicine and vinca alkaloids. These are thought to act primarily through β-tubulin, thereby interfering with the normal processes
of tubulin polymer formation and disassembly.
Nomenclature tubulin
alpha 1a
tubulin
alpha 4a
tubulin beta class I tubulin beta 3
class III
tubulin beta 4B
class IVb
tubulin beta 8
class VIII
HGNC,
UniProt
TUBA1A,
Q71U36
TUBA4A,
P68366
TUBB, P07437 TUBB3, Q13509 TUBB4B, P68371 TUBB8, Q3ZCM7
Inhibitors – – vinblastine (pIC50 9), vincristine, eribulin (pIC50 8.2)
[58], paclitaxel (pEC50 8.1) [61], colchicine (pIC50 8)
[13], cabazitaxel, docetaxel, ixabepilone
combretastatin A4
(pIC50 8.2) [22]
– –
Further reading on Tubulins
Gadadhar S et al. (2017) The tubulin code at a glance. J Cell Sci 130: 1347-1353 [PMID:28325758] Penna LS et al. (2017) Anti-mitotic agents: Are they emerging molecules for cancer treatment?
Pharmacol Ther 173: 67-82 [PMID:28174095]
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